Biologic therapy of psoriatic arthritis.
Psoriatic arthritis is now recognized as a potentially serious and disabling disease. Traditional therapies have not been very effective in controlling signs and symptoms or preventing progression of damage. Based on the pathogenesis of the disease new therapies have been introduced, particularly anti-TNF agents and anti-T cell agents. Several of those have shown excellent responses in clinical variables, health related quality of life and function, and in preventing radiological progression. However, not all patients have responded, and the long-term safety of these drugs remains unknown.
Gladman
D D
DD
Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada. dafna.gladman@utoronto.ca
D000068879:Adalimumab; D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy*; D001691:Biological Therapy / Q000379:methods*; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D000068800:Etanercept; D019317:Evidence-Based Medicine; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*